
Thomas C. Diaz
Examiner (ID: 5729, Phone: (571)270-5461 , Office: P/3656 )
| Most Active Art Unit | 3656 |
| Art Unit(s) | 3617, 3656, 3682 |
| Total Applications | 1182 |
| Issued Applications | 780 |
| Pending Applications | 84 |
| Abandoned Applications | 349 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19701436
[patent_doc_number] => 12195445
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-14
[patent_title] => 2-amino-N-heteroaryl-nicotinamides as Na
[patent_app_type] => utility
[patent_app_number] => 17/752419
[patent_app_country] => US
[patent_app_date] => 2022-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 60130
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17752419
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/752419 | 2-amino-N-heteroaryl-nicotinamides as Na | May 23, 2022 | Issued |
Array
(
[id] => 17837645
[patent_doc_number] => 20220274950
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-01
[patent_title] => LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME
[patent_app_type] => utility
[patent_app_number] => 17/749569
[patent_app_country] => US
[patent_app_date] => 2022-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21940
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749569
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/749569 | Lanthionine c-like protein 2 ligands, cells prepared therewith, and therapies using same | May 19, 2022 | Issued |
Array
(
[id] => 17896958
[patent_doc_number] => 20220306620
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 17/747384
[patent_app_country] => US
[patent_app_date] => 2022-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32456
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17747384
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/747384 | PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS | May 17, 2022 | Abandoned |
Array
(
[id] => 19343548
[patent_doc_number] => 20240252511
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => METHODS OF TREATING DEPRESSION AND ANXIETY
[patent_app_type] => utility
[patent_app_number] => 18/560763
[patent_app_country] => US
[patent_app_date] => 2022-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9998
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18560763
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/560763 | METHODS OF TREATING DEPRESSION AND ANXIETY | May 15, 2022 | Pending |
Array
(
[id] => 19279840
[patent_doc_number] => 20240216312
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE
[patent_app_type] => utility
[patent_app_number] => 18/289211
[patent_app_country] => US
[patent_app_date] => 2022-05-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15768
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 335
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18289211
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/289211 | PPAR-AGONISTS FOR USE IN THE TREATMENT OF LIVER FAILURE | May 9, 2022 | Pending |
Array
(
[id] => 18994575
[patent_doc_number] => 11911392
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-27
[patent_title] => Non-catalytic substrate-selective p38a-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/740248
[patent_app_country] => US
[patent_app_date] => 2022-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 44825
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17740248
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/740248 | Non-catalytic substrate-selective p38a-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity, and methods of use thereof | May 8, 2022 | Issued |
Array
(
[id] => 19889043
[patent_doc_number] => 20250114355
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-04-10
[patent_title] => TREATING LIVER DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/289047
[patent_app_country] => US
[patent_app_date] => 2022-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20596
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18289047
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/289047 | TREATING LIVER DISEASE | May 8, 2022 | Pending |
Array
(
[id] => 18361123
[patent_doc_number] => 20230142714
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => KETONE INHIBITORS OF LYSINE GINGIPAIN
[patent_app_type] => utility
[patent_app_number] => 17/740260
[patent_app_country] => US
[patent_app_date] => 2022-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51502
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 375
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17740260
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/740260 | Ketone inhibitors of lysine gingipain | May 8, 2022 | Issued |
Array
(
[id] => 18109508
[patent_doc_number] => 20230002388
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS
[patent_app_type] => utility
[patent_app_number] => 17/739855
[patent_app_country] => US
[patent_app_date] => 2022-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67881
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17739855
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/739855 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | May 8, 2022 | Issued |
Array
(
[id] => 18153062
[patent_doc_number] => 11566023
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-31
[patent_title] => Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/738216
[patent_app_country] => US
[patent_app_date] => 2022-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 40
[patent_no_of_words] => 46075
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17738216
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/738216 | Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof | May 5, 2022 | Issued |
Array
(
[id] => 18604646
[patent_doc_number] => 11746095
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-09-05
[patent_title] => Inhibtors of RAF kinases
[patent_app_type] => utility
[patent_app_number] => 17/738327
[patent_app_country] => US
[patent_app_date] => 2022-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26114
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17738327
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/738327 | Inhibtors of RAF kinases | May 5, 2022 | Issued |
Array
(
[id] => 19265204
[patent_doc_number] => 20240208903
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => ACID ADDITION SALTS OF (S)-3-(2,5-DIMETHOXY-4-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE AND (S)-3-(2-METHOXY-5-(METHYLTHIO)-4-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE, SPECIFIC POLYMORPHS THEREOF AND METHODS FOR THEIR MANUFACTURE
[patent_app_type] => utility
[patent_app_number] => 18/556295
[patent_app_country] => US
[patent_app_date] => 2022-05-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17885
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556295
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/556295 | ACID ADDITION SALTS OF (S)-3-(2,5-DIMETHOXY-4-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE AND (S)-3-(2-METHOXY-5-(METHYLTHIO)-4-(TRIFLUOROMETHYL)PHENYL)PIPERIDINE, SPECIFIC POLYMORPHS THEREOF AND METHODS FOR THEIR MANUFACTURE | May 4, 2022 | Pending |
Array
(
[id] => 19658426
[patent_doc_number] => 20240425491
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-26
[patent_title] => HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 18/288711
[patent_app_country] => US
[patent_app_date] => 2022-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 88649
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18288711
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/288711 | HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | May 3, 2022 | Pending |
Array
(
[id] => 19345180
[patent_doc_number] => 20240254143
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-01
[patent_title] => OREXIN RECEPTOR AGONISTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/558245
[patent_app_country] => US
[patent_app_date] => 2022-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50881
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -39
[patent_words_short_claim] => 15
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18558245
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/558245 | OREXIN RECEPTOR AGONISTS AND USES THEREOF | May 2, 2022 | Pending |
Array
(
[id] => 19210679
[patent_doc_number] => 11999727
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-04
[patent_title] => Compounds and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/732846
[patent_app_country] => US
[patent_app_date] => 2022-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 481377
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 483
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17732846
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/732846 | Compounds and methods of use | Apr 28, 2022 | Issued |
Array
(
[id] => 18216400
[patent_doc_number] => 11591322
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-02-28
[patent_title] => Certain chemical compositions and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/731943
[patent_app_country] => US
[patent_app_date] => 2022-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 29798
[patent_no_of_claims] => 29
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 704
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17731943
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/731943 | Certain chemical compositions and methods of use thereof | Apr 27, 2022 | Issued |
Array
(
[id] => 18187497
[patent_doc_number] => 11578066
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-02-14
[patent_title] => Fluoroalkyl-oxadiazoles and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/731949
[patent_app_country] => US
[patent_app_date] => 2022-04-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58677
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17731949
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/731949 | Fluoroalkyl-oxadiazoles and uses thereof | Apr 27, 2022 | Issued |
Array
(
[id] => 19279870
[patent_doc_number] => 20240216342
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => BLOOD CARNITINE-INCREASING AGENT
[patent_app_type] => utility
[patent_app_number] => 18/556912
[patent_app_country] => US
[patent_app_date] => 2022-04-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5367
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18556912
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/556912 | BLOOD CARNITINE-INCREASING AGENT | Apr 26, 2022 | Pending |
Array
(
[id] => 19497545
[patent_doc_number] => 20240336563
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-10-10
[patent_title] => G-ALPHA-S INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/287634
[patent_app_country] => US
[patent_app_date] => 2022-04-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56038
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18287634
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/287634 | G-ALPHA-S INHIBITORS AND USES THEREOF | Apr 25, 2022 | Pending |
Array
(
[id] => 17830001
[patent_doc_number] => 20220267305
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/727386
[patent_app_country] => US
[patent_app_date] => 2022-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56378
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 654
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17727386
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/727386 | Modulators of estrogen receptor proteolysis and associated methods of use | Apr 21, 2022 | Issued |